LALina Maria Rayo Abella

Lina Maria Rayo Abella

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lina Maria Rayo Abella has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clozapine acts as an antagonist of human dopamine D1 receptors in the atrium

    by Rayo Abella, Lina Maria, Britt Hofmann, Tom Lars Neubert, Joachim Neumann, Ulrich Gergs

    Clozapine is one of the oldest antipsychotic drugs, the first atypical neuroleptic drug, and can be found in the World Health Organization’s list of essential drugs. The precise mechanism of action of clozapine as an antipsychotic is not known. However, clozapine binds to many proteins in vitro. The objective of this study was to investigate the role of the dopamine D 1 receptor as a possible explanation for the cardiac side effects of clozapine. To this end, the hypothesis was tested that clozapine reduces the positive inotropic or positive chronotropic effects mediated by human cardiac dopamine D 1 receptors using a novel transgenic mouse model with cardiac myocyte-specific expression of the human dopamine D 1 receptor (D 1 -TG). The force of contraction in the left (LA) and right (RA) atria of adult D 1 -TG mice and, as a control, wild-type (WT) mice was measured and compared to human right atrial preparations (HAP), which were obtained from adult patients with coronary heart disease during cardiac surgery. In the presence of propranolol, which was used to block endogenous β-adrenoceptors, dopamine increased the force of contraction in LA and elevated the beating rate in RA from D 1 -TG. The effects in RA, but not in LA, were antagonized by clozapine. The effects were more pronounced in the presence of haloperidol, a typical antipsychotic drug. This drug was studied for comparison in mouse atrial preparations and was found to antagonize the effects of dopamine in both LA and RA. Furthermore, clozapine decreased dopamine receptor–stimulated contractile force in HAP. These findings suggest that the D 1 receptor antagonism may contribute to cardiac side effects associated with clozapine in patients.

  • Open Access

    Felcisetrag stimulates 5-HT4-serotonin receptors in the human atrium

    by Lina Maria Rayo Abella, Joachim Neumann, Britt Hofmann, Uwe Kirchhefer, Ulrich Gergs

    Felcisetrag (methyl 4-[[4-[[(2-propan-2-yl-1 H -benzimidazole-4-carbonyl)-amino]-methyl]-piperidin-1-yl]methyl]piperidine-1-carboxylate, TD-8954, TAK-954) has a structural formula with similarity to serotonin. It is one of the most potent compounds to bind to recombinant human 5-HT 4 -serotonin receptors. We noted that felcisetrag raised force of contraction in left atrial preparations (LA) and beating rate in right atrial preparations (RA) from mice with cardiac-specific overexpression of the human 5-HT 4 receptors (5-HT 4 -TG) but was inactive in LA and RA from adult wild type mouse hearts (WT). When felcisetrag had increased force of contraction in LA or beating rate in RA of 5-HT 4 -TG, GR125487, a 5-HT 4 receptor antagonist, reduced force of contraction and beating rate. Felcisetrag raised force of contraction only in the presence of cilostamide in human right atrial preparations (HAP) obtained from adult patients during open heart surgery due to severe coronary heart disease. These positive inotropic effects of felcisetrag in HAP were attenuated by 1 µM GR125487. In the presence of cilostamide, 100 nM felcisetrag exerted positive inotropic effects that were increased further by 1 µM serotonin. When 1 µM serotonin had raised force of contraction, additionally applied 100 nM felcisetrag reduced force of contraction in HAP. These data suggest that felcisetrag can act as an agonist as well as an antagonist at human 5-HT 4 receptors in the mammalian heart.


  • Open Access

    Clebopride stimulates 5-HT4-serotonin receptors in the human atrium

    by Lina Maria Rayo Abella, Joachim Neumann, Britt Hofmann, Uwe Kirchhefer, Ulrich Gergs

    Clebopride resembles in its structural formula metoclopramide. Clebopride, an approved drug, is used to treat gastrointestinal diseases. Here, we tested the hypothesis that clebopride like metoclopramide acts as a partial agonist at human cardiac 5-HT4-serotonin-receptors. Clebopride enhanced the force of contraction (FOC) in isolated, electrically stimulated (1 Hz) left atrial preparations (LA) from transgenic mice with cardiac specific overexpression of the human 5-HT4-serotonin receptors (5-HT4-TG). Subsequently applied GR125487 (1 µM), a specific 5-HT4-serotonin-receptor antagonist, diminished this positive inotropic effect (PIE) of clebopride in LA from 5-HT4-TG. Clebopride failed to heighten FOC in LA from littermate wild-type mouse hearts (WT). Clebopride augmented the beating rate in isolated right atrial preparations (RA) from 5-HT4-TG but unable to do so in RA from WT. Clebopride alone (up to 10 µM) failed to augment FOC in isolated electrically stimulated (1Hz) human right atrial preparations (HAP) obtained during open heart surgery from adult patients with severe coronary heart disease. Interestingly, in the presence of the phosphodiesterase III inhibitor cilostamide, clebopride heightened FOC in HAP. GR125487 attenuated this PIE in HAP. Furthermore, when 1 µM serotonin had raised FOC in HAP, additionally applied 10 µM clebopride diminished FOC in HAP. We conclude that clebopride can act as an agonist and as an antagonist at 5-HT4-serotonin receptors in the human atrium.


  • Open Access

    Bromopride stimulates 5-HT4-serotonin receptors in the human atrium

    by Lina Maria Rayo Abella, Joachim Neumann, Britt Hofmann, Ulrich Gergs

    Bromopride, an analogue of metoclopramide, is approved in some countries to treat gastrointestinal diseases. These therapeutic effects of bromopride are explained by antagonism at D2-dopamine receptors in the gut and the brain. We tested here the hypothesis that bromopride acts as an agonist or antagonist at the human cardiac 5-HT4-serotonin receptors. To this end, the force of contraction (FOC) was measured in isolated human atrial preparations (HAP), in isolated left atrial preparations (LA), and in isolated spontaneously beating right atrial (RA) preparations from mice with cardiac specific overexpression of the human 5-HT4-serotonin receptors (5-HT4-TG). Bromopride concentration dependently increased FOC in LA from 5-HT4-TG. The positive inotropic effect (PIE) of bromopride in LA from 5-HT4-TG was abolished by GR125487, a 5-HT4-serotonin receptor antagonist. Only in the presence of the phosphodiesterase III inhibitor cilostamide did bromopride raise FOC under isometric conditions in HAP. The PIE of 10 µM bromopride in HAP was extinguished by 1 µM GR125487. When serotonin had elevated FOC in HAP, additionally applied bromopride reduced FOC. These data suggest that bromopride is a partial agonist at human cardiac 5-HT4-serotonin receptors.


  • Open Access

    Stimulation of histamine H1-receptors produces a positive inotropic effect in the human atrium

    by Thanh Hoai Pham, Lina Maria Rayo Abella, Katarina Hadova, Jan Klimas, Stefan Dhein, Steffen Pockes, Jonas Manfred Albert Schlicht, Britt Hofmann, Uwe Kirchhefer, Joachim Neumann, et al.

    There is a controversy whether histamine H1-receptor activation raises or lowers or does not affect contractility in the human heart. Therefore, we studied stimulation of H1-receptors in isolated electrically stimulated (one beat per second) human atrial preparations (HAP). For comparison, we measured force of contraction in left atrial preparations (LA) from mice with overexpression of the histamine H1-receptor in the heart (H1-TG). We detected the messenger ribonucleic acid (mRNA) expression of human histamine H1-receptors in HAP. In LA from H1-TG, each cumulatively applied concentration of histamine and a dual H1/H2-agonist called 2-(2-thiazolyl)-ethylamine (ThEA) caused a time-dependent initial negative inotropic effect followed over time by a lasting positive inotropic effect. Both effects were concentration-dependent in LA from H1-TG. After 100 µM cimetidine, 10 µM histamine exercised a positive inotropic effect in HAP that was diminished by 10 µM mepyramine, an H1-receptor antagonist. The concentrations of mepyramine and cimetidine used here are based on the work of others and our own work (e.g., Guo et al. J Cardiovasc Pharmacol. 6:1210-5 1984, Rayo Abella et al. J Pharmacol Exp Ther. 389:174-185 2024). Similarly, we observed that ThEA (10 µM, 30 µM, 100 µM cumulatively applied) induced a concentration- and time-dependent positive inotropic effect in HAP. In HAP, we detected never negative inotropic effects to either histamine or ThEA. The positive inotropic effects to ThEA in HAP were reduced by mepyramine. The positive inotropic effects of ThEA in LA from H1-TG and in HAP were not accompanied by reductions in the time of tension relaxation. We conclude that stimulation of histamine H1-receptors only increases and does not decrease force of contraction in the HAP in our patients.


  • Open Access

    Contractile effects of stimulation of D1-dopamine receptors in the isolated human atrium

    by U. Gergs, T. H. Pham, L. M. Rayo Abella, C. Hesse, P. Grundig, S. Dhein, B. Hofmann, J. Neumann

    Dopamine receptors have been claimed not to directly increase contractility in the human heart. Therefore, we performed contraction experiments in isolated electrically driven human atrial preparations (HAP). For comparison, we performed contraction experiments with left atrial preparations of transgenic mice which harbor a cardiac overexpression of human D1-dopamine receptors (D1-TG). In D1-TG, first we noted that dopamine (10 nM–10 µM cumulatively applied) in the presence of propranolol exerted a concentration- and time-dependent positive inotropic effect in D1-TG. In a similar fashion, dopamine increased force of contraction in the presence of 0.4 µM propranolol in HAP and these effects were amplified by pre-treatment with inhibitor of phosphodiesterase III (1 µM) cilostamide. Moreover, contractile effects of dopamine in the presence of propranolol 0.4 µM in HAP were antagonized by odapipam, haloperidol, or raclopride. Ten micromolars of fenoldopam in the presence of cilostamide increased force of contraction in HAP and this effect was antagonized by SCH 23390. We conclude that stimulation of human D1-dopamine receptors can increase force of contraction in the HAP.


  • Open Access

    Initial characterization of a transgenic mouse with overexpression of the human D1-dopamine receptor in the heart

    by Lina Maria Rayo Abella, Hannes Jacob, Christin Hesse, Britt Hofmann, Sarah Schneider, Lisa Schindler, Max Keller, Igor B. Buchwalow, CongYu Jin, Pertti Panula, et al.

    Dopamine can exert effects in the mammalian heart via five different dopamine receptors. There is controversy whether dopamine receptors increase contractility in the human heart. Therefore, we have generated mice that overexpress the human D1-dopamine receptor in the heart (D1-TG) and hypothesized that dopamine increases force of contraction and beating rate compared to wild-type mice (WT). In D1-TG hearts, we ascertained the presence of D1-dopamine receptors by autoradiography using [3H]SKF 38393. The mRNA for human D1-dopamine receptors was present in D1-TG hearts and absent in WT. We detected by in-situ-hybridization mRNA for D1-dopamine receptors in atrial and ventricular D1-TG cardiomyocytes compared to WT but also in human atrial preparations. We noted that in the presence of 10 µM propranolol (to antagonize β-adrenoceptors), dopamine alone and the D1- and D5-dopamine receptor agonist SKF 38393 (0.1–10 µM cumulatively applied) exerted concentration- and time-dependent positive inotropic effects and positive chronotropic effects in left or right atrial preparations from D1-TG. The positive inotropic effects of SKF 38393 in left atrial preparations from D1-TG led to an increased rate of relaxation and accompanied by and probably caused by an augmented phosphorylation state of the inhibitory subunit of troponin. In the presence of 0.4 µM propranolol, 1 µM dopamine could increase left ventricular force of contraction in isolated perfused hearts from D1-TG. In this model, we have demonstrated a positive inotropic and chronotropic effect of dopamine. Thus, in principle, the human D1-dopamine receptor can couple to contractility in the mammalian heart.


  • Open Access

    OR-1896 increases force of contraction in the isolated human atrium

    by Lina M. Rayo-Abella, Peter Grundig, Max N. Bernhardt, Britt Hofmann, Joachim Neumann, Ulrich Gergs

    OR-1896 ((R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide) is the main active metabolite of levosimendan. However, nobody has reported a positive inotropic effect of OR-1896 in isolated human cardiac preparations. The mechanism of action of OR-1896 remains controversial. Hence, we wanted to know whether OR-1896 exerts a positive inotropic effect in humans and what might be the underlying mechanism. Therefore, we measured the contractile effects of OR-1896 (0.01–10 µM cumulatively applied) in isolated electrically stimulated (1 Hz) human right atrial preparations (HAP) obtained during cardiac surgery. OR-1896, given alone, exerted time- and concentration-dependent positive inotropic effects; 1-µM OR-1896 increased force by 72 ± 14.7% (p < 0.05, n = 6) and shortened the time of relaxation by 10.6 ± 3.6% (p < 0.05, n = 11) in HAP started at 0.1 µM, plateaued at 1-µM OR-1896, and was antagonized by 1-µM propranolol. The maximum positive inotropic effect of OR-1896 in human right atrial preparations was less than that of 10-µM isoprenaline. EMD 57033 (10 µM), a calcium sensitizer, enhanced the force of contraction further in the additional presence of 1-µM OR-1896 by 109 ± 19% (p < 0.05, n = 4). Cilostamide (10 µM), an inhibitor of phosphodiesterase III given before OR-1896 (1 µM), blocked the positive inotropic effect of OR-1896 in HAP. Our data suggest that OR-1896 is, indeed, a positive inotropic agent in the human heart. OR-1896 acts as a PDE III inhibitor. OR-1896 is unlikely to act as a calcium sensitizer in the human heart.